3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Follicular
5
Lymphoma, Non-Hodgkin
2
Recurrence
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
venetoclax
69
Cyclophosphamide
53
ibrutinib
44
obinutuzumab
43
acalabrutinib
42
Rituximab
40
fludarabine
37
fludarabine phosphate
30
Specimen Handling
29
pirtobrutinib
25
Biopsy
24
zanubrutinib
23
Whole-Body Irradiation
16
Bendamustine Hydrochloride
15
Magnetic Resonance Spectroscopy
14
Mycophenolic Acid
13
Lenalidomide
11
Peripheral Blood Stem Cell Transplantation
9
Sirolimus
8
idelalisib
7
Tacrolimus
7
CT-P10
7
ARQ531
7
tafasitamab
6
Prednisone
6
Busulfan
6
pembrolizumab
5
Stem Cell Transplantation
5
Melphalan
5
Interleukin-2
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Lymphocytic, Chronic, B-Cell
×
R-CHOP protocol
×
1 year
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled